Read the latest research from the Christie lab @PeterMacRes on MHCII and whole genome duplication in ovarian cancer, published with @SpringerNature in @NatureComms https://t.co/0nZEMq1ObW
Delighted to see this really important step forward in the care of women with cancer: ovarian toxicity assessment must be standard in oncology trials. Great work from @ASCO led by @cuiwanda and Kelly-Anne Philips
Assessing ovarian toxicity in clinical trials is way overdue! 🪺 We’re so proud of these recommendations published in @TheLancetOncol
Check them out here 👉🏼 https://t.co/mofMvMAdCa
Knowing if a cancer treatment affects fertility or triggers early menopause is vital info for women and yet is rarely a focus of clinical trials. A new @ASCO statement - by @CuiWanda, @drkellyphillips and colleagues - aims to change this. More: https://t.co/cZ9qWpqZqg
🚨 New @ASCO recommendations published in @TheLancetOncol. We need to better understand the impacts of cancer therapies on ovarian function so that patients have information about the risks to fertility and other longterm health implications from early menopause @drkellyphillips
Our new recommendations published today in @TheLancetOncol spotlight the need for assessing ovarian toxicity in #ClinicalTrials. This aims to bridge the information gap helping patients make informed treatment choices. ➡️ https://t.co/WmCLToIQPQ #OncTwitter
Absolute honour to work with the COSA Fertility Preservation Guidelines Working Group and publish our Perspective piece in the MJA today! 🌼 @COSAoncology@WCMICS@thewomens @UniMelbMDHS
Will be joining #teamTOGA to raise money for lung cancer research
Help me catch up to @reswong impressive fundraising effort using the link below 👇🏻
https://t.co/ddYI2nU6H2
Our #TeamTOGA Melbourne contingent is up & running with @reswong turning in a fantastic weekend effort >$1.8K
The 3km walk entries are now open https://t.co/YRoEhT7r4w
Set up yr fundraising page https://t.co/wQr3c2XWqA
Join our team of @DrMelMoore@CuiWanda Jackie Yoong...
#LCSM
So exciting to see this new work published on immunotherapy impacts to fertility @NatureCancer. This research strongly advocates we must include reproductive endpoints in clinical trials moving forward! https://t.co/zocPqElZvz
Immunotherapies are revolutionising cancer treatment.. but they raced into the clinic with some oversights of possible side effects. Our new data alerts women & clinicians to potential risks to fertility & highlights the need to prioritise human studies https://t.co/dlspClV2OA
An important study showing ICI causes ovarian tox in mice
❗️antiPDL1 & antiCTLA4 depleted primordial follicles by 50% & 46%
❗️increase in atretic secondary & antral follicles
We need to assess ovarian tox in trials!
@HuttLab@HuttKarla@amy_winship@LoiSher@drkellyphillips
Also check out our E-poster describing the clinical outcomes of pts with uncommon EGFR mutations that received SACT. ORR of 47% in those that received 1L TKIs. We need to find these pts so we can treat with targeted therapy. @IASLC#WCLC22